Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion

被引:33
作者
Dammann, HG [1 ]
Fuchs, W [1 ]
Richter, G [1 ]
Burkhardt, F [1 ]
Wolf, N [1 ]
Walter, TA [1 ]
机构
[1] TAKEDA PHARMA GMBH,AACHEN,GERMANY
关键词
D O I
10.1046/j.1365-2036.1997.157332000.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: To investigate, by means of meal-stimulated acid secretion, the extent to which differences in plasma half-life, bioavailability and the recommended therapeutic dose can influence the antisecretory potency of lansoprazole and omeprazole, Methods: In this double-blind, placebo-controlled, crossover study, 10 healthy male volunteers received 15 mg or 30 mg lansoprazole, 20 mg or 40 mg omeprazole or placebo for 5 days, in a randomized order. Meal-stimulated acid secretion was determined by means of a homogenized test meal and intragastric titration. Results: On day 1, meal-stimulated acid secretion was decreased by 35% and 45% after administration of 15 mg or 30 mg lansoprazole, and by 16% and 42% after 20 mg or 40 mg omeprazole. After 3 and 5 days of dosing the decreases were 53% and 48% with 15 mg lansoprazole, 82% and 82% with 30 mg lansoprazole, 43% and 39% with 20 mg omeprazole, and 76% and 83% with 40 mg omeprazole. At all measuring points during the 5-day dosing periods, lansoprazole 15 mg and 30 mg proved superior to 20 mg omeprazole in inhibiting meal-stimulated gastric acid secretion, but the differences were only statistically significant for the lansoprazole 30 mg dose. 30 mg lansoprazole and 40 mg omeprazole proved equipotent, On day 1 only 30 mg lansoprazole was significantly better than placebo. Conclusion: This study demonstrated the following order of antisecretory potency: 30 mg lansoprazole = 40 mg omeprazole > 15 mg lansoprazole approximate to 20 mg omeprazole.
引用
收藏
页码:359 / 364
页数:6
相关论文
共 25 条
[1]   PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
SKANBERG, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563
[2]  
ANDERSSON T, 1990, Drug Investigation, V2, P255
[3]   LANSOPRAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND ITS THERAPEUTIC EFFICACY IN ACID-RELATED DISORDERS [J].
BARRADELL, LB ;
FAULDS, D ;
MCTAVISH, D .
DRUGS, 1992, 44 (02) :225-250
[4]  
BECK A, 1978, KRAFTFUTTER, V3, P118
[5]  
DELHOTALLANDES B, 1993, EUR J CLIN PHARMACOL, V45, P367
[6]   GASTRIC-ACID SECRETION RATE AND BUFFER CONTENT OF STOMACH AFTER EATING - RESULTS IN NORMAL SUBJECTS AND IN PATIENTS WITH DUODENAL-ULCER [J].
FORDTRAN, JS ;
WALSH, JH .
JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (03) :645-657
[7]  
FREUND H, 1996, J VERDAUUNGSKRANKHEI, V14, P56
[8]  
GARG SK, 1992, INT J CLIN PHARM TH, V31, P96
[9]   Pharmacokinetics and absolute bioavailability of lansoprazole [J].
Gerloff, J ;
Mignot, A ;
Barth, H ;
Heintze, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (04) :293-297
[10]   OMEPRAZOLE INHIBITS OXIDATIVE DRUG-METABOLISM - STUDIES WITH DIAZEPAM AND PHENYTOIN INVIVO AND 7-ETHOXYCOUMARIN INVITRO [J].
GUGLER, R ;
JENSEN, JC .
GASTROENTEROLOGY, 1985, 89 (06) :1235-1241